Franklin K. Johnson
About
Franklin K. Johnson is a scholar working on Physiology, Public Health, Environmental and Occupational Health and Molecular Biology.
According to data from OpenAlex, Franklin K. Johnson has authored 40 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Physiology, 12 papers in Public Health, Environmental and Occupational Health and 9 papers in Molecular Biology. Recurrent topics in Franklin K. Johnson's work include Lysosomal Storage Disorders Research (16 papers), Opioid Use Disorder Treatment (11 papers) and Pain Management and Opioid Use (9 papers). Franklin K. Johnson is often cited by papers focused on Lysosomal Storage Disorders Research (16 papers), Opioid Use Disorder Treatment (11 papers) and Pain Management and Opioid Use (9 papers). Franklin K. Johnson collaborates with scholars based in United States, Canada and United Kingdom. Franklin K. Johnson's co-authors include Joseph Stauffer, K. V. I. Rolston, Arshag D. Mooradian, Bramah N. Singh, Carl M. Mendel, Ken Fujioka, F. Gilbert McMahon, Everton Rowe, Beatrice Setnik and Nathaniel P. Katz and has published in prestigious journals such as PLoS ONE, Clinical Pharmacology & Therapeutics and Journal of Pain and Symptom Management.
In The Last Decade
Franklin K. Johnson
39 papers receiving 678 citations
Peers
Franklin K. Johnson
Ute Richarz Switzerland
Ram P. Kapil United States
Paula Burger United States
George D. Olsen United States
Bojan Lalovic United States
JO Svensson Sweden
C. W. Hand United Kingdom
Lise Eliot Canada
Stephen Daniels United States
Karen J. Regina United States
Citations per year, relative to Franklin K. Johnson Franklin K. Johnson (= 1×)
peers
Ute Richarz
Countries citing papers authored by Franklin K. Johnson
Since
Specialization
Citations
This map shows the geographic impact of Franklin K. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franklin K. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franklin K. Johnson more than expected).
Fields of papers citing papers by Franklin K. Johnson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Franklin K. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franklin K. Johnson. The network helps show where Franklin K. Johnson may publish in the future.
Co-authorship network of co-authors of Franklin K. Johnson
This figure shows the co-authorship network connecting the top 25 collaborators of Franklin K. Johnson. A scholar is included among the top collaborators of Franklin K. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franklin K. Johnson. Franklin K. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Byrne, Barry J., Giancarlo Parenti, Benedikt Schoser, et al.. (2024). Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease. Frontiers in Neurology. 15. 1451512–1451512.
2.
Johnson, Franklin K., Shirley Wu, Hadis Williams, et al.. (2024). Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment. PLoS ONE. 19(12). e0314030–e0314030.
3.
Byrne, Barry J., Benedikt Schoser, Priya S. Kishnani, et al.. (2023). Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). Journal of Neurology. 271(4). 1787–1801.
4.
Mulberg, Andrew E., Christina Bucci‐Rechtweg, Joseph Giuliano, et al.. (2019). Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders. Orphanet Journal of Rare Diseases. 14(1). 36–36.
5.
Kishnani, Priya S., Mark A. Tarnopolsky, K Sivakumar, et al.. (2012). T.P.46 A novel phase 2a study design to investigate drug-drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alpha-glucosidase in subjects with Pompe disease. Neuromuscular Disorders. 22(9-10). 852–852.
6.
Johnson, Franklin K., et al.. (2011). Effects of Alcohol on the Pharmacokinetics of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules. The Journal of Clinical Pharmacology. 52(5). 747–756.
7.
Webster, Lynn R., et al.. (2011). Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users. Drugs in R&D. 11(3). 259–275.
8.
Johnson, Franklin K., et al.. (2010). Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Advances in Therapy. 27(11). 846–858.
9.
Johnson, Franklin K., et al.. (2010). Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: A single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clinical Therapeutics. 32(6). 1149–1164.
10.
Johnson, Franklin K., et al.. (2010). The Relative Bioavailability of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules (EMBEDA®) and an Extended Release Morphine Sulfate Capsule Formulation (KADIAN®) in Healthy Adults Under Fasting Conditions. American Journal of Therapeutics. 18(1). 2–8.
11.
Webster, Lynn R., Randall P. Brewer, Chao Wang, et al.. (2010). Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and Sequestered Naltrexone, in Patients with Chronic, Moderate to Severe Pain. Journal of Pain and Symptom Management. 40(5). 734–746.
12.
Stauffer, Joseph, et al.. (2009). Subjective Effects and Safety of Whole and Tampered Morphine Sulfate and Naltrexone Hydrochloride (ALO-01) Extended-Release Capsules versus Morphine Solution and Placebo in Experienced Non-Dependent Opioid Users. Clinical Drug Investigation. 29(12). 777–790.
13.
Katz, Nathaniel P., et al.. (2009). ALO-01 (Morphine Sulfate and Naltrexone Hydrochloride) Extended-Release Capsules in the Treatment of Chronic Pain of Osteoarthritis of the Hip or Knee: Pharmacokinetics, Efficacy, and Safety. Journal of Pain. 11(4). 303–311.
14.
Johnson, Franklin K., et al.. (2008). Effect of Concomitant Ingestion of Alcohol on the In Vivo Pharmacokinetics of KADIAN (Morphine Sulfate Extended-Release) Capsules. Journal of Pain. 9(4). 330–336.
15.
Abdel‐Rahman, Susan M., Franklin K. Johnson, James D. Connor, et al.. (2004). Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine. Journal of Pediatric Gastroenterology and Nutrition. 38(4). 442–451.
16.
Abdel‐Rahman, Susan M., Franklin K. Johnson, James D. Connor, et al.. (2004). Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine. Journal of Pediatric Gastroenterology and Nutrition. 38(4). 442–451.
17.
Blum, Robert A., et al.. (2003). Pharmacokinetics and Pharmacodynamics of a Novel Nizatidine Controlled‐Release Formulation in Healthy Subjects. The Journal of Clinical Pharmacology. 43(1). 74–83.
18.
Abdel‐Rahman, Susan M., Franklin K. Johnson, Neil Manowitz, Gregory B. Holmes, & Gregory L. Kearns. (2002). Single-Dose Pharmacokinetics of Nizatidine (Axid®) in Children. The Journal of Clinical Pharmacology. 42(10). 1089–1096.
19.
Abdel‐Rahman, Susan M., Franklin K. Johnson, Neil Manowitz, Gregory B. Holmes, & Gregory L. Kearns. (2002). Single‐Dose Pharmacokinetics of Nizatidine (Axid®) in Children. The Journal of Clinical Pharmacology. 42(10). 1089–1096.
20.
McMahon, F. Gilbert, Ken Fujioka, Bramah N. Singh, et al.. (2000). Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension. Archives of Internal Medicine. 160(14). 2185–2185.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ute Richarz Breakdown of academic impact, for papers by Ram P. Kapil Breakdown of academic impact, for papers by Paula Burger Breakdown of academic impact, for papers by George D. Olsen Breakdown of academic impact, for papers by Bojan Lalovic Breakdown of academic impact, for papers by JO Svensson Breakdown of academic impact, for papers by C. W. Hand Breakdown of academic impact, for papers by Lise Eliot Breakdown of academic impact, for papers by Stephen Daniels Breakdown of academic impact, for papers by Karen J. Regina